IDH1 and epilepsy: An important marker for survival in patient with diffuse glioma is isocitrate dehydrogenase (IDH) mutation (IDH‐mut), which is associated with better prognosis but higher epilepsy prevalence (Chen et al., 2017; Yan et al., 2009).